Loading clinical trials...
Loading clinical trials...
A Phase 2b Randomized, Active-Controlled, Double-Blind Trial to Investigate Safety, Efficacy, and Dose-response of BMS-955176, Given on a Backbone of Tenofovir/Emtricitabine, in Treatment-Naive HIV-1 Infected Adults
The purpose of this study is to find at least one dose of BMS-955176 that will be safe, effective and tolerable for HIV-1 infected treatment naive adults.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
GSK Investigational Site
Beverly Hills, California, United States
GSK Investigational Site
Los Angeles, California, United States
GSK Investigational Site
DeLand, Florida, United States
GSK Investigational Site
Atlanta, Georgia, United States
GSK Investigational Site
Decatur, Georgia, United States
GSK Investigational Site
Santa Fe, New Mexico, United States
GSK Investigational Site
Tulsa, Oklahoma, United States
GSK Investigational Site
Fort Worth, Texas, United States
GSK Investigational Site
Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina
GSK Investigational Site
Rosario, Santa Fe Province, Argentina
Start Date
May 12, 2015
Primary Completion Date
May 26, 2016
Completion Date
August 21, 2017
Last Updated
September 19, 2018
210
ACTUAL participants
BMS-955176
DRUG
EFV
DRUG
TDF/FTC
DRUG
Lead Sponsor
ViiV Healthcare
Collaborators
NCT06719310
NCT02831673
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT02075593